journal
MENU ▼
Read by QxMD icon Read
search

Neurology and Therapy

journal
https://www.readbyqxmd.com/read/30415358/authors-response-to-the-letter-to-the-editor-regarding-a-comprehensive-review-on-copemyl-%C3%A2
#1
LETTER
Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, Claudio Gasperini, Enrico Montanari, Pierluigi Navarra, Francesco Patti, Maria Pia Sormani, Angelo Ghezzi
No abstract text is available yet for this article.
November 10, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30415357/patient-and-physician-perspectives-in-a-case-of-severe-traumatic-brain-injury
#2
Rhoderick M Casis
Traumatic brain injury is a challenge for general practitioners and specialists worldwide due to the heterogeneous clinical picture, secondary injuries and complex treatment including surgery, medication, intensive care, nutrition and rehabilitation. This case report is about a TBI patient with a score of four on the Glasgow Coma Scale when she was transferred from the primary hospital to our center. Her condition, treatment options and expectations were discussed with the relatives. The patient was subjected to surgery and received pharmacologic intervention including a neurotrophic drug and extensive rehabilitation measures including occupational therapy...
November 10, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30415356/letter-to-the-editor-regarding-a-comprehensive-review-on-copemyl-%C3%A2
#3
LETTER
Giancarlo Comi, Ferdinando Nicoletti, Pier Luigi Canonico, Diego Centonze
No abstract text is available yet for this article.
November 10, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30414084/patient-power-revolution-in-multiple-sclerosis-navigating-the-new-frontier
#4
David Yeandle, Peter Rieckmann, Gavin Giovannoni, Nektaria Alexandri, Dawn Langdon
A debate on shared decision making in multiple sclerosis (MS) was led by a patient advocate and leading neurologists from the MS in the 21st Century Steering Group. Key themes and salient points which emerged from the debate and audience discussions are reported in this article. Arguments against shared decision making included the fact that physicians study and practice for years to reach their level of expertise, and that the level of understanding required to make these decisions may not be possible to communicate to patients within time-limited consultations...
November 9, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30361858/phase-1-parkinson-s-disease-studies-show-the-dopamine-d1-d5-agonist-pf-06649751-is-safe-and-well-tolerated
#5
U Shivraj Sohur, David L Gray, Sridhar Duvvuri, Yao Zhang, Kathleen Thayer, Gang Feng
INTRODUCTION: There is a need for new therapies in Parkinson's disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson's disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamics of PF-06649751 were assessed in single ascending dose and multiple ascending dose clinical trials in patients with Parkinson's disease. The single ascending dose study (N = 18) was a double-blind, placebo-controlled study with a three-way crossover design consisting of three treatment periods separated by 7-day study drug washout periods...
October 25, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30315481/european-and-american-guidelines-for-multiple-sclerosis-treatment
#6
Angelo Ghezzi
The management and treatment of multiple sclerosis (MS) is becoming more and more complex as many medications are now available, with different routes of administration, mechanisms of action, and effectiveness and safety profiles. The decision-making process to choose the right medication is a complex task requiring a careful evaluation of the results of clinical and post-marketing studies, and the capability to translate data from clinical studies to patients in everyday clinical practice. Two European neurological societies, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and European Academy of Neurology (EAN), and the American Academy of Neurology (AAN) have recently delivered guidelines for MS treatment, helping neurologists to address the most common clinical issues related to this topic...
October 12, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30293098/burden-of-migraine-in-europe-using-self-reported-digital-diary-data-from-the-migraine-buddy%C3%A2-application
#7
Pamela Vo, Nicolas Paris, Aikaterini Bilitou, Tomas Valena, Juanzhi Fang, Christel Naujoks, Ann Cameron, Frederic de Reydet de Vulpillieres, Francois Cadiou
INTRODUCTION: Migraine is a neurological disease characterized by recurring attacks that can cause severe disabling pain. This study described the burden of migraine as reported by individuals with migraine in the real world using a mobile application. METHODS: A retrospective, cross-sectional analysis was conducted using data captured through the Migraine Buddy© smartphone application from adult, self-diagnosed individuals with migraine in 17 European countries...
October 6, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30255467/decreased-behavioral-abnormalities-after-treatment-with-combined-donepezil-and-yokukansankachimpihange-in-alzheimer-disease-an-observational-study-the-osaki-tajiri-project
#8
Kenichi Meguro, Satoshi Yamaguchi
INTRODUCTION: Yokukansan is one of the traditional herbal medicines (Kampo medicine in Japan) commonly used in the treatment of the Behavioral and Psychological Symptoms of Dementia (BPSD). We performed an observational study using yokukansankachimpihange, which contains a nobiletin-rich Citrus reticulata, to determine whether it could improve BPSD as well as cognitive impairment in patients with Alzheimer disease (NINCDS-ADRDA). METHODS: Forty-six (23 vs. 23) patients were enrolled in the study sample (donepezil group vs...
September 25, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30251237/dibenzazepine-agents-in-epilepsy-how-does-eslicarbazepine-acetate-differ
#9
Charlotte Lawthom, Jukka Peltola, Rob McMurray, Emma Dodd, Vicente Villanueva
Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL) belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act as sodium channel blockers (SCBs). However, ESL is structurally distinct from CBZ and OXC, resulting in differences in metabolism, pharmacokinetics, and pharmacodynamics. Despite a lack of direct comparative data, evidence for potential differences in effectiveness and tolerability within the dibenzazepine family has emerged from studies in which patients being treated with one dibenzazepine agent have received adjunctive treatment with another (having achieved insufficient seizure control with the first) or have transitioned from one dibenzazepine agent to another because of lack of effectiveness or poor tolerability...
September 24, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30167914/practical-evidence-based-recommendations-for-patients-with-multiple-sclerosis-who-want-to-have-children
#10
REVIEW
Yara Dadalti Fragoso, Tarso Adoni, Joseph B Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K Parolin, Henry K Sato, Daniel Lima Varela, Claudia Cristina F Vasconcelos
Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal) evidence of disease activity. The development and commercialization of new drugs has led to a renewed interest in family planning, since patients with MS may face a future with reduced (or no) disease-related neurological disability. The advice of neurologists is often sought by patients who want to have children and need to know more about disease control at conception and during pregnancy and the puerperium. When MS is well controlled, the simple withdrawal of drugs for patients who intend to conceive is not an option...
August 30, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30094699/injection-of-onabotulinum-toxin-a-into-the-bilateral-external-oblique-muscle-attenuated-camptocormia-a-prospective-open-label-study-in-six-patients-with-parkinson-s-disease
#11
Hiroyuki Todo, Hiroshi Yamasaki, Go Ogawa, Katsuya Nishida, Naonobu Futamura, Itaru Funakawa
INTRODUCTION: Camptocormia (severe bending of the spine) is a debilitating complication of Parkinson's disease (PD) without established treatment. Botulinum toxin (BT) may be beneficial, but data is scarce regarding the efficacy of administration of BT into the bilateral external oblique (EO) muscle for treatment of camptocormia in PD. METHODS: Six patients with PD and camptocormia, with flexion of the thoracic spine, were enrolled in the study. BT (75 or 90 units, onabotulinum toxin A) were injected into each EO bilaterally under sonographic guidance...
August 9, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30084001/real-world-observational-evaluation-of-hair-thinning-in-patients-with-multiple-sclerosis-receiving-teriflunomide-is-it-an-issue-in-clinical-practice
#12
Lori Hendin Travis, Annette Okai, Steve Cavalier, Darren Stam, Lisa Farnett, Keith R Edwards
INTRODUCTION: Hair thinning occurred in 10-14% of teriflunomide-treated patients in the teriflunomide multiple sclerosis clinical development program, compared with 5% of placebo-treated patients. Our objective was to examine the clinical course of hair thinning in patients in an observational real-world project. METHODS: Patients with relapsing-remitting multiple sclerosis who reported hair thinning to healthcare professionals (HCPs) during treatment with teriflunomide were eligible for inclusion...
August 6, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30073497/characterizing-the-high-disease-burden-of-transthyretin-amyloidosis-for-patients-and-caregivers
#13
Michelle Stewart, Shannon Shaffer, Brian Murphy, Jane Loftus, Jose Alvir, Michael Cicchetti, William R Lenderking
INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a progressive, debilitating, and often fatal, rare disease requiring significant caregiver support. This study aims to better characterize the burden of disease for ATTR amyloidosis patients and caregivers. METHODS: Patients and caregivers in the USA and Spain were recruited through patient advocacy groups to complete a cross-sectional survey...
August 2, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/30027457/antipsychotic-related-movement-disorders-drug-induced-parkinsonism-vs-tardive-dyskinesia-key-differences-in-pathophysiology-and-clinical-management
#14
REVIEW
Kristen M Ward, Leslie Citrome
INTRODUCTION: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement disorders associated with exposure to dopamine receptor blocking agents such as antipsychotics, but they differ in their pathophysiology and clinical management. Treatment for one may worsen the other, and there are important diagnostic clues that assist in making an accurate assessment and instituting a rational treatment plan. METHODS: A literature review was executed to identify articles relating to the presentation, pathophysiology, epidemiology, and management of DIP and TD...
July 19, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29987534/a-review-of-dementia-with-lewy-bodies-impact-diagnostic-criteria-and-treatment
#15
REVIEW
Samuel D Capouch, Martin R Farlow, Jared R Brosch
Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer's disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer's disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses...
July 9, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29956263/monitoring-progressive-multiple-sclerosis-with-novel-imaging-techniques
#16
REVIEW
Maria Petracca, Monica Margoni, Giulia Bommarito, Matilde Inglese
Imaging markers for monitoring disease progression in progressive multiple sclerosis (PMS) are scarce, thereby limiting the possibility to monitor disease evolution and to test effective treatments in clinical trials. Advanced imaging techniques that have the advantage of metrics with increased sensitivity to short-term tissue changes and increased specificity to the structural abnormalities characteristic of PMS have recently been applied in clinical trials of PMS. In this review, we (1) provide an overview of the pathological features of PMS, (2) summarize the findings of research and clinical trials conducted in PMS which have applied conventional and advanced magnetic resonance imaging techniques and (3) discuss recent advancements and future perspectives in monitoring PMS with imaging techniques...
June 28, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29923070/a-systematic-review-and-meta-analysis-of-the-brief-cognitive-assessment-for-multiple-sclerosis-bicams
#17
REVIEW
Freya Corfield, Dawn Langdon
Multiple sclerosis (MS) is a neurological disease of the central nervous system which can lead to a range of severe physical disabilities. A large proportion of those affected will experience cognitive impairment, which is associated with a worse prognosis. Effective assessment of cognition in MS has been problematic due to a lack of suitable scales. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) was developed in 2010 as part of an international endeavour to facilitate cognitive assessment...
June 19, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29881979/only-follow-up-of-memory-b-cells-helps-monitor-rituximab-administration-to-patients-with-neuromyelitis-optica-spectrum-disorders
#18
Christine Lebrun, Mikael Cohen, Maria Alessandra Rosenthal-Allieri, Saskia Bresch, Sylvia Benzaken, Romain Marignier, Barbara Seitz-Polski, Michel Ticchioni
INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) are identified as a spectrum of inflammatory demyelinating disorders involving the brain, spinal cord and optic nerves. These disorders require early diagnosis and highly active immunosuppressive treatment. Rituximab (RTX) has demonstrated efficacy in limiting relapse in NMOSD when using several administration schedules. We questioned if the CD19+ CD27+ memory B cell count was a more reliable marker to monitor RTX administration than the RTX plasma level and CD19+ B cell count...
June 7, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29728891/5ht6-antagonists-in-the-treatment-of-alzheimer-s-dementia-current-progress
#19
REVIEW
Megan Andrews, Babak Tousi, Marwan N Sabbagh
Alzheimer's disease is an important condition with a considerable and unmet disease burden in large need of continued research and more treatment options. The 5HT6 antagonists are a new class of medications to be offered. Because they are pro-cholinergic, these medications are to be used as adjuncts to acetylcholinesterase inhibitors (such as donepezil), further increasing acetylcholine in the central nervous system (CNS). Early trials of the 5HT6 antagonists showed improvements in cognition and activities of daily living when used as adjuncts to current therapies for Alzheimer's dementia...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29704098/author-s-response-to-the-letter-to-the-editor-regarding-practical-treatment-of-lewy-body-disease-in-the-clinic-patient-and-physician-perspectives
#20
LETTER
Elisabet Londos
No abstract text is available yet for this article.
June 2018: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"